Paper Details

  1. Home
  2. Paper Details

Place of next generation acute migraine specific treatments among triptans, non-responders and contraindications to triptans and possible combination therapies.

Author: AshinaMessoud, SouzaMarcio Nattan Portes, VerhagenIris Elsa, de BoerIrene

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review summarizes the literature on next-generation acute migraine therapies, including ditans (lasmiditan) and gepants (rimegepant and ubrogepant), as alternatives to triptans. While the new therapies show promise, head-to-head trials are needed to determine their place in migraine treatment.
Paper Details　
Original Abstract of the Article :
<b>Background:</b> For many years triptans have been the cornerstone of acute migraine treatment. Nevertheless, treatment with triptans may not always be initiated due to contraindications (seen in approximately one fifth of patients) or inadequate response (seen in approximately one third of patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1177/03331024221143773

データ提供：米国国立医学図書館（NLM）

Next Generation Acute Migraine Treatments: Exploring New Oases in the Desert of Migraine

Migraine, a debilitating neurological condition, can have a profound impact on quality of life. Triptans have been the mainstay of acute migraine treatment for many years. However, they are not effective for all patients and have certain contraindications. New acute migraine therapies, such as ditans (lasmiditan) and gepants (rimegepant and ubrogepant), offer promising alternatives. This review explores the place of these next-generation treatments in the landscape of acute migraine management.

New Oases in the Desert of Migraine: Exploring Next-Generation Therapies

The review highlights the potential of ditans and gepants as effective alternatives for patients who do not respond to triptans or have contraindications. These new drugs have distinct mechanisms of action, offering hope for broader coverage and a more effective approach to managing acute migraine attacks. However, further research is needed to fully understand their efficacy and safety compared to triptans and to explore the potential benefits of combination therapy.

Navigating the Desert of Migraine: Finding the Right Treatment Path

This review underscores the importance of finding the right treatment path for each individual experiencing migraine. While triptans have been a valuable tool for many years, next-generation therapies like ditans and gepants offer promising alternatives for those who have not found success with triptans or have specific contraindications. It's crucial to work closely with a healthcare professional to explore all available options and find the most effective and safe treatment plan.

Dr. Camel's Conclusion

The desert of migraine can be a place of intense pain and discomfort. This review, like a well-equipped camel caravan, provides insights into new and promising treatment options. By exploring the potential of next-generation therapies, we can help individuals find a more comfortable and sustainable journey through the desert of migraine.

Date :
  1. Date Completed 2023-02-07
  2. Date Revised 2023-02-08
Further Info :

Pubmed ID

36739516

DOI: Digital Object Identifier

10.1177/03331024221143773

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.